RAPT Therapeutics Competitors

Myovant Sciences (NYSE:MYOV) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Myovant Sciences and RAPT Therapeutics, as provided by MarketBeat.com.

Myovant Sciences presently has a consensus price target of $32.1667, suggesting a potential upside of 55.62%. RAPT Therapeutics has a consensus price target of $42.00, suggesting a potential upside of 119.67%. Given RAPT Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe RAPT Therapeutics is more favorable than Myovant Sciences.

Risk & Volatility

Myovant Sciences has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

Insider and Institutional Ownership

33.8% of Myovant Sciences shares are owned by institutional investors. Comparatively, 65.0% of RAPT Therapeutics shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 31.0% of RAPT Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Myovant Sciences and RAPT Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Myovant Sciences and RAPT Therapeutics' revenue, earnings per share and valuation.

Myovant Sciences is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

RAPT Therapeutics beats Myovant Sciences on 7 of the 11 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Insider & Institutional Ownership

65.0% of RAPT Therapeutics shares are owned by institutional investors. 31.0% of RAPT Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

RAPT Therapeutics has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares RAPT Therapeutics and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares RAPT Therapeutics and Ironwood Pharmaceuticals' revenue, earnings per share and valuation.

Ironwood Pharmaceuticals has higher revenue and earnings than RAPT Therapeutics. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for RAPT Therapeutics and Ironwood Pharmaceuticals, as provided by MarketBeat.

RAPT Therapeutics currently has a consensus price target of $42.00, indicating a potential upside of 119.67%. Ironwood Pharmaceuticals has a consensus price target of $11.50, indicating a potential upside of 3.05%. Given RAPT Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe RAPT Therapeutics is more favorable than Ironwood Pharmaceuticals.

Summary

Ironwood Pharmaceuticals beats RAPT Therapeutics on 7 of the 13 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for RAPT Therapeutics and Morphic, as provided by MarketBeat.

RAPT Therapeutics presently has a consensus target price of $42.00, indicating a potential upside of 119.67%. Morphic has a consensus target price of $85.00, indicating a potential upside of 72.59%. Given RAPT Therapeutics' higher probable upside, research analysts plainly believe RAPT Therapeutics is more favorable than Morphic.

Risk & Volatility

RAPT Therapeutics has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Insider and Institutional Ownership

65.0% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 61.5% of Morphic shares are held by institutional investors. 31.0% of RAPT Therapeutics shares are held by insiders. Comparatively, 39.5% of Morphic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares RAPT Therapeutics and Morphic's top-line revenue, earnings per share (EPS) and valuation.

RAPT Therapeutics has higher earnings, but lower revenue than Morphic. Morphic is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares RAPT Therapeutics and Morphic's net margins, return on equity and return on assets.

Summary

Morphic beats RAPT Therapeutics on 6 of the 11 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and Five Prime Therapeutics (NASDAQ:FPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Valuation & Earnings

This table compares RAPT Therapeutics and Five Prime Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

RAPT Therapeutics has higher earnings, but lower revenue than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares RAPT Therapeutics and Five Prime Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

65.0% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 31.0% of RAPT Therapeutics shares are held by insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for RAPT Therapeutics and Five Prime Therapeutics, as provided by MarketBeat.

RAPT Therapeutics presently has a consensus price target of $42.00, indicating a potential upside of 119.67%. Five Prime Therapeutics has a consensus price target of $30.7143, indicating a potential downside of 19.17%. Given RAPT Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe RAPT Therapeutics is more favorable than Five Prime Therapeutics.

Volatility & Risk

RAPT Therapeutics has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, suggesting that its share price is 340% more volatile than the S&P 500.

Summary

RAPT Therapeutics beats Five Prime Therapeutics on 9 of the 13 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and Cytokinetics (NASDAQ:CYTK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Profitability

This table compares RAPT Therapeutics and Cytokinetics' net margins, return on equity and return on assets.

Volatility & Risk

RAPT Therapeutics has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for RAPT Therapeutics and Cytokinetics, as provided by MarketBeat.

RAPT Therapeutics presently has a consensus price target of $42.00, indicating a potential upside of 119.67%. Cytokinetics has a consensus price target of $35.5455, indicating a potential upside of 46.16%. Given RAPT Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe RAPT Therapeutics is more favorable than Cytokinetics.

Valuation & Earnings

This table compares RAPT Therapeutics and Cytokinetics' top-line revenue, earnings per share (EPS) and valuation.

RAPT Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.0% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Cytokinetics shares are held by institutional investors. 31.0% of RAPT Therapeutics shares are held by insiders. Comparatively, 6.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

RAPT Therapeutics beats Cytokinetics on 7 of the 13 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for RAPT Therapeutics and MacroGenics, as reported by MarketBeat.com.

RAPT Therapeutics currently has a consensus target price of $42.00, indicating a potential upside of 119.67%. MacroGenics has a consensus target price of $34.7778, indicating a potential upside of 20.17%. Given RAPT Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe RAPT Therapeutics is more favorable than MacroGenics.

Insider & Institutional Ownership

65.0% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of MacroGenics shares are owned by institutional investors. 31.0% of RAPT Therapeutics shares are owned by company insiders. Comparatively, 9.0% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares RAPT Therapeutics and MacroGenics' net margins, return on equity and return on assets.

Volatility & Risk

RAPT Therapeutics has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.

Earnings and Valuation

This table compares RAPT Therapeutics and MacroGenics' gross revenue, earnings per share (EPS) and valuation.

RAPT Therapeutics has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

RAPT Therapeutics beats MacroGenics on 8 of the 13 factors compared between the two stocks.